Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Sillj HH
It's 'at what point does continued benefit justify continued injections.' For most patients, that threshold is around six months of active use
Research buyers should not flatten all evidence into one proof category
Journal of Environmental Science and Health Part C, 37 (1), 2641
Well, welcome back to the show, Sarah, and thank you for helping us out with this claim about hair loss side effects with GLP-1s
In the present study, we showed that GLP-1 receptor was present in the intima and media and that its expression level was lower in obese subjects